Citations

Clear

2429 citation(s) found for "Shah, SS".

Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hot-Spots
Toumeh, Nadia , Jabban, Yazan, Nanaa, Ahmad , He, Rong , Viswanatha, David S., Foran, James M. , Yi, Cecilia Y. Arana , Saliba, Antoine N. , Shah, Meera , Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Alkhateeb, Hassan B. , Al‐Kali, Aref , Saliba, Antoine N. , Viswanatha, David, Arana Yi, Cecilia Y , Saliba, Antoine N , Hefazi Torghabeh, Mehrdad, Hogan, William J , Shah, Mithun V , Alkhateeb, Hassan B , Al-Kali, Aref , Saliba, Antoine N , Jevremović, Dragan , Yi, Cecilia Arana , Hefazi, Mehrdad , Hogan, William J.

Mayo Clinic

Hematology Reports | May 8, 2025 | Volume: 17 | Issue: 3 | Pages: 26

10.3390/hematolrep17030026 | PMID 40407636 Get It

Background/Objectives: DDX41, DEAD-box RNA helicase 41 gene located on chromosome 5q25.3, is one of the most mutated genes in patients with germline predisposition to myeloid neoplasms. Germline and somatic mutations often have different locations and patterns of mutation, with some hotspots displaying diversity based on ethnicity. We aimed to explore clinical outcomes in patients with various DDX41 hot-spot mutations. Methods: This was a retrospective study of patients at Mayo Clinic with DDX41 mutation identified through Next Generation Sequencing (NGS) between 2018 and 2024. We completed unadjusted comparisons using continuous or categorical variables, and survival rates were assessed using the Kaplan–Meier method and cox regression analysis. Results: Overall survival appears to be higher in those with p.M1| when compared to p.Asp140GlyFs*2 and p.Arg525His, with comparable survival between p.Arg525His and p.Asp140GlyFs*2. Among males with p.M1| who underwent bone marrow transplant, those who underwent bone marrow transplant appeared to have lower survival rates, although not statistically significant. Our study was limited by a small sample size, therefore limiting our ability to reach significance. Conclusions: Our findings suggest potential implications for clinical outcomes based on DDX41 mutation hot-spots.
Characteristics and Outcomes of Infantile Hemangioma With Non, Poor, and Partial Response to Standard-Dose Systemic Beta-Blocker Therapy
Afarideh, Mohsen , Baisi, Katinna E. Rodriguez , Aghazadeh, Nessa , Morel, Kimberly D. , Olsen, Gerilyn M. , Adams, Denise M. , Nopper, Amy J., Garzón, Maria C. , Horii, Kimberly A., Lauren, Christine T. , Mathes, Erin F., McCuaïg, Catherine , Newell, Brandon , Powell, Julie, Shah, Sonal D. , Tollefson, Megha M. , Aghazadeh Mohandesi, Nessa , Baselga, Eulàlia , Frieden, Ilona J. , Powell, Julie

Mayo Clinic

Journal of Vascular Anomalies | April 25, 2025 | Volume: 6 | Issue: 2 | Pages: e112

10.1097/jova.0000000000000112 Get It

Objectives: Systemic beta-blockers are highly effective for the management of infantile hemangiomas (IH), but little is known about infants who do not adequately respond. We aimed to describe the characteristics and outcomes of suboptimal responders to standard-dose systemic beta-blockers in infants with IH. Methods: This is a multicenter retrospective cohort study to evaluate demographics, IH lesion characteristics, and treatment specifics of infants with IH with suboptimal response to baseline standard-dose propranolol treatment. Clinical response was used to assess the outcome after a therapeutic change. Results: Twenty-five infants were included in this study. Seven (28%) had segmental IH, 16 (64%) focal, and 2 (8%) indeterminate. The IHs were located on the head and neck in 21 (84%) infants, with 24 (96%) having a deep or combined component. Therapy changes after standard-dose propranolol treatment failure, most commonly by escalating propranolol dose to ≥2.5 mg/kg/d (59%) or surgical interventions (29%), were associated with good therapeutic effects. Conclusion: Among suboptimal responders to standard-dose systemic propranolol, IHs with a deep or combined component and located on the head and neck were the most common. This retrospective study was largely descriptive in nature with additional exploratory analyses. However, it is still encouraging that for patients with a suboptimal clinical response, higher propranolol doses of ≥2.5–3 mg/kg/d or second-line treatments with surgical interventions or systemic steroids can be considered as potentially safe and effective alternatives. Level of evidence: Level 4 (case series).
Global Barriers to Otolaryngology Care
Patterson, Rolvix H. , Bangash, Ali Haider , Pandey, Akansha, Elwell, Zachary , Adeyemo, Adebolajo A. , Cahill, Gabrielle , Cherches, Alexander , Daudu, Davina , Der, Carolina , Din, Taseer , Hapunda, Racheal , Ibekwe, Titus , Maina, Ivy W. , Mukuzi, Allan, Nakku, Doreen , Petrucci, Beatriz, Pietrobon, Carolina, Salano, Valerie , Sprow, Holly N. , Waterworth, Christopher J. , Wiedermann, Joshua P. , Xu, Mary Jue , Alkire, Blake C., Okerosi, Samuel , Initiative, Global Otolaryngology–Head and Neck Surgery, Bhutta, Mahmood F. , Dillard, Lauren K. , Ncogoza, Isaie , Lin, H.C., Potent, Keith, Adel, Iman, Wiedermann, Joshua , Cherches, Alexander D , Din, Taseer , Ncogoza, Isaie , Bangash, Ali Haider , Patterson, Rolvix H , Zalaquett, Nader , Pandey, Akansha, Nuss, Sarah , Fei‐Zhang, David J. , Srinivasan, Tarika , Fagan, Johannes J. , Kahinga, Aveline Aloyce , Seguya, Amina , Shaye, David , Smith, Emily R. , Tamir, Sharon Ovnat , Wen, Christopher Z. , Initiative, Global Otolaryngology–Head and Neck Surgery, Shah, Keshav V. , Potent, Keith

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | April 24, 2025 | Volume: 151 | Issue: 6 | Pages: 604

10.1001/jamaoto.2025.0573 | PMID 40272811 Get It

ImportanceUnderstanding the global barriers to otolaryngology–head and neck surgery (OHNS) care is crucial in addressing disparities in access to care, particularly in low-income and middle-income countries (LMICs).ObjectiveTo characterize barriers to comprehensive otolaryngology care across World Bank income groups.Design, Setting, and ParticipantsUsing an online cross-sectional survey that was administered by the Global OHNS Initiative via international and national professional societies, personal contacts, and social media, this study captured the perceptions of otolaryngologists regarding barriers to OHNS care at the levels of the country, health sector, clinician, and patient. Participants included otolaryngologists from the 194 World Health Organization member states and Taiwan. Eligibility criteria included a medical degree and specialized training in managing conditions of the ear, nose, and throat. The nonresponse rate was not recorded. The data collection period spanned from October 2022 to June 2023.ExposuresExposures included World Bank income group classification.Main Outcomes and MeasuresThe primary outcomes were Likert scale responses regarding frequency of barriers to OHNS care. The a priori hypothesis was that LMICs would report more frequent barriers to OHNS care.ResultsThe study involved 146 otolaryngologists (47 female individuals [32%]), with 69 (47%) from high-income countries and 77 (53%) from LMICs. Male individuals represented 45 high-income country respondents (65%) and 54 LMIC respondents (70%). Barriers were reported across income groups at all levels of the health system, with a higher frequency in LMICs. Several barriers were reported to be more substantial in LMICs, such as the national volume and distribution of otolaryngologists, financial compensation for clinicians, and patient stigma, and others were common across income settings, such as the availability of operating rooms and inflexible working hours. Common concerns included national and health sector barriers: OHNS workforce, referral networks, government support; clinician barriers: excessive clinician workloads, understaffing, poor administration support; patient barriers: distance to health care facilities, financial burdens such as medical costs and foregone wages, stigma, and health literacy.Conclusions and RelevanceThe results of this cross-sectional study suggest that there are barriers to otolaryngology care globally that affected all levels of the health care system. This work may inform prioritization of otolaryngology within research and policy, and it emphasizes the need for effective strategies to expand access to otolaryngology care, particularly in lower-income settings.
Abstract 2787: Effect of miR-494 modulation in colorectal cancer (CRC): Clinical outcome, target expression and cell characteristics
Millstein, Joshua , Ashouri, Karam , Algaze, Sandra, Yang, Yan , Gonzalez, Lesly Torres, Shah, Unnati Hemant, Zhang, Wu , Lenz, H., Torres‐Gonzalez, Lesly , Mittal, Pooja , Soni, Shivani , Battaglin, Francesca , Algaze, Sandra , Jayachandran, Priya , Yang, Yan , Ou, Fang‐Shu , Venook, Alan P. , Singh, Indrakant Kumar

Mayo Clinic

Cancer Research | April 22, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2787-2787

10.1158/1538-7445.am2025-2787 Get It

Background. MicroRNAs are small, single-stranded non-coding RNA molecules that play major role in gene regulation. miRNAs have been reported as both tumor suppressive and oncogenic and are promising candidates for cancer prognosis and treatment. miR-494 is known to promote cell migration and invasion in CRC. Our study aimed to further explore the role of miR-494 modulation (inhibition and overexpression) in CRC. Methods. We evaluated the impact of tumor gene expression of MIR494 on outcomes (overall survival: OS; progression-free survival: PFS) in data for 433 metastatic CRC (mCRC) patients (pts) (bevacizumab [bev] (N = 226) vs cetuximab [cet] (N = 207)) enrolled in randomized phase III CALGB/SWOG 80405 trial obtained from Alliance for Clinical Trials in Oncology. RNA extracted from FFPE tumor samples was sequenced using the HiSeq 2500 (Illumina). Gene expression was divided into high, medium and low. Associations were assessed by log-rank test and multivariable Cox proportional hazards regression model. Treatment-gene interactions were analyzed using the likelihood ratio test. CRC cell lines HCT116 and HT29 were transfected with miR-494 inhibitors and mimics for 48 hours and total RNA was collected, followed by RT-qPCR (miR-494 and target genes BMAL1, PAK1, CDH1, CDH2, SNAI1, TWIST) and clonogenic assays. Results. High miR-494 was significantly associated with worse PFS in overall (median survival: high vs low: 9.3 vs 11.3 months, P<0.025) and cet-treated (median survival high vs low: 9.2 vs 9.6 months, P<0.025) mCRC cohorts, while no significance was observed in bev-treated mCRC. Multivariable Cox model showed significant association between high miR-494 and worse PFS and OS in the cet-treated cohort; however, treatment-gene interaction was not statistically significant. Expression analysis revealed miR-494 was significantly reduced and increased following inhibitor and mimic transfection, respectively. Differential gene expression of the target genes analyzed was observed between the miR-494 inhibitor and mimic-treated HCT116 and HT29 samples. In HCT116 cells, inhibition of miR-494 significantly (P < 0.01) reduced expression of PAK1, while increased the expression of CDH1. The number of colonies formed relatively increased after transfection with miR-494 inhibitor compared to miR-494 mimic. Conclusion. Our findings showed that high miR-494 expression correlated with worse PFS overall and in cet-treated mCRC pts. It would be interesting to check for potential associations with EGFR signaling (direct or indirect). Further studies are warranted for efficient targeting and to gain better understanding of the associated signaling involved in miR-494 modulation in CRC. Support: U10CA180821, U10CA180882; U10CA180888 (SWOG): Genentech. https://acknowledgments.alliancefound.org; P30CA014089, UG1CA180830 [HJL]. Clinicaltrials.gov Identifier: NCT00265850 Citation Format: Pooja Mittal, Joshua Millstein, Shivani Soni, Francesca Battaglin, Karam Ashouri, Sandra Algaze, Priya Jayachandran, Yan Yang, Lesly T. Gonzalez, Unnati H. Shah, Wu Zhang, Fang-Shu Ou, Alan P. Venook, Indrakant K. Singh, Heinz J. Lenz. Effect of miR-494 modulation in colorectal cancer (CRC): Clinical outcome, target expression and cell characteristics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2787.
Abstract 6620: Low interferon expression coupled with 9p21 loss in non-small cell lung cancer (NSCLC) patients associated with distinct somatic landscape, altered immune population, and poorer response to immune checkpoint inhibitor (ICI) therapies
Symons, Jessica L. , Rhead, Brooke , Levantakos, Konstantinos, Vokes, Natalie I. , Shah, Pooja A. , Treviño, Santiago , Fragkogianni, Stamatina , Chao, Calvin Y. , Rodon, Jordi

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 6620-6620

10.1158/1538-7445.am2025-6620 Get It

Abstract Deletions in 9p21 are common across multiple cancer types including NSCLC. Notably, 9p21 deletions have been implicated in an immune-excluded tumor immune phenotype and worse outcomes following ICIs. Whether this effect is due to CDKN2A loss, collateral loss of MTAP, or loss of type I interferon genes (IFNK, IFNA) has not been fully adjudicated. The Tempus Database (Tempus AI, Inc., Chicago, IL) was queried for de-identified records of patients with NSCLC and DNA (Tempus xT) and RNA (Tempus xR) molecular profiling. CDKN2A/MTAP deleted samples were defined as those containing biallelic loss of CDKN2A/B and MTAP. As IFNK is not included in the DNA sequencing bait set, IFNK status was defined as low in any sample with expression ≤ the first quartile of IFNK expression from samples with intact CDKN2A/B and MTAP. Samples with tumor purity < 40% or mixed loss of CDKN2A/B and MTAP were excluded. Association analysis of CDKN2A/MTAP/IFNK status with other genomic events and clinical outcomes was performed. N=16, 947 patients were included in the overall analysis, of whom n=1, 991 had CDKN2A/B/MTAP deletion (11.7%, CMdel). Significantly more CMdelpatients had low IFNK expression compared to CDKN2A/B/MTAP intact (CMwt) patients (n=14, 956); of CMdel(n=1300), 65.3% had high IFNK expression (IFNKhi) and 34.7% had low IFNK expression (IFNKlo). Among CMdelpatients, IFNKhisamples were enriched in never smokers compared to IFNKlopatients (24% vs 18%, p=0.002). CMdel was enriched in samples with EGFR and ALK driver alterations, and depleted in samples with KRAS or TP53 alterations. In both CMdeland CMwtcontexts, KRAS, EGFR, and ALK alterations associated with IFNKhiexpression, whereas TP53, NFE2L2, STK11, KEAP1, SMARCA4, and KMT2D associated with IFNKloexpression. IFNKhiexpression within CMdelpatients was associated with an increase in the estimated proportion of immune cell subpopulations, including CD8 T cells and macrophages (M1 and M2), and a decrease in neutrophils and NK cells. In metastatic/unresectable stage III patients with recorded ICI-containing 1L therapies (n=1, 795), patients with CMdeland IFNKlotrended toward higher rates of progressive disease (PD) (37%), whereas CMdel/IFNKhihad comparable rates of PD to CMwtl/IFNKhiand CMwtl/IFNKlo(28%, 27%, 30%, respectively). CMdel/IFNKlopatients treated with non-ICI/TKI therapies (mostly consisting of chemotherapy) had a non-significant trend toward increased rate of PD (63%). CMdelassociates with driver alterations in EGFR and ALK, along with worse ICI and chemotherapy outcomes in the context of IFNKlobut not IFNKhi expression. Further work to disentangle the impact of immune infiltrate and the co-mutation landscape will help clarify the underlying associated biology. Citation Format: Natalie Vokes, Jessica L. Symons, Brooke Rhead, Pooja A. Shah, Santiago Trevino, Konstantinos Levantakos, Stamatina Fragkogianni, Calvin Chao, Jordi A. Rodon. Low interferon expression coupled with 9p21 loss in non-small cell lung cancer (NSCLC) patients associated with distinct somatic landscape, altered immune population, and poorer response to immune checkpoint inhibitor (ICI) therapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6620.
Abstract 7415: Association between sleep traits and risk of non-Hodgkin's lymphoma subtypes: a mendelian randomization study in the International Lymphoma Epidemiology (InterLymph) Consortium
Shah, Pankhil, Crawford, Brittany, Macauda, Angelica , Hildebrandt, Michelle A.T., Caporaso, Neil E., Yeager, Meredith, Dean, Michael , Goldin, Lynn R. , Camp, Nicola J. , Casabonne, Delphine , Nieters, Alexandra, Chanock, Stephen J., Machiela, Mitchell J., Conry, Michael , Cheah, Simon , Brown, Elizabeth E. , Vachon, Celine M. , Berndt, Sonja I. , McKay, James , Hjalgrim, Henrik, Sucheston‐Campbell, Lara, Machiela, Mitchell J. , Machiela, Mitchell J , Merchant, Anwar T. , Birmann, Brenda M. , Hildebrandt, Michelle A.T. , Norman, Aaron D. , Yeager, Meredith , Vivo, Immaculata De , Waller, Rosalie G. , Canzian, Federico , Unal, Pelin, Ziv, Elad , Marinac, Catherine R. , Nieters, Alexandra , Chanock, Stephen Jacob , Zhong, Charlie , Park, Hanla A. , Hofmann, Jonathan N. , Vachon, Celine M. , Slager, Susan L. , Wang, Sophia , Vijai, Joseph , Smith-Byrne, Karl , Clay‐Gilmour, Alyssa

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 7415-7415

10.1158/1538-7445.am2025-7415 Get It

Abstract Introduction: With over 80, 000 new cases of non-Hodgkin's lymphoma (NHL) diagnosed annually, modifiable risk factors remain unclear. Circadian disruption, linked to cancers like breast and prostate, affects immune cells (e.g., natural killer cells and T-helper cells) by altering their trafficking and proliferation. Some studies (PMID: 30566672, 27611440) suggest long sleep may increase overall NHL risk, including a Mendelian randomization (MR) study (PMID: 32895918). However, no research has examined the causal relationship between sleep traits, including long sleep, and NHL risk, by subtypes. We hypothesize that sleep traits are causally associated with NHL subtypes in European populations, testing this using MR with data from the International Lymphoma Epidemiology Consortium (InterLymph). Methods: We conducted two-sample MR using genome-wide association studies (GWAS) summary data for sleep traits and NHL subtypes. Only independent, genome-wide significant (p < 5×10-8) Single Nucleotide Polymorphisms (SNPs) were selected as valid instruments, sourced from the UK Biobank. Sleep traits included chronotype (153 SNPs), insomnia (48 SNPs), sleep duration (78 SNPs), excessive daytime sleepiness (37 SNPs), short sleep (27 SNPs), and long sleep (8 SNPs). NHL subtype data were from InterLymph: follicular lymphoma (6, 508 cases / 64, 183 controls), mantle cell lymphoma (1, 169 cases / 61, 603 controls), Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL: 1, 697 cases / 59, 333 controls), and chronic lymphocytic leukemia (8, 522 cases / 67, 653 controls). The primary analysis used inverse-variance weighted (IVW) random-effects, with MR-Egger for pleiotropy adjustment. Results: Using the IVW method, we did not identify any statistically significant causal association between sleep traits and the risk of NHL subtypes, but did yield several intriguing trends. Long sleep (sleep duration >= 9 h per night) showed a marginally increased NHL risk [Odds ratio (OR) range: 1.51 - 247.9] across each subtype. Short sleep (sleep duration < 7 h per night) showed a similar trend [OR range: 1.25 - 1.81], except for WM/LPL, where we noticed a negative trend. The confidence limit for long sleep was imprecise due to the small number of variants. We did not notice any significant directional horizontal pleiotropy or weak instrument bias. Conclusions: We found no conclusive evidence of a relationship between sleep traits and four NHL subtypes. However, we see suggestive trends of long and short sleep associated with higher risk of some NHL subtypes. These findings align with the previous studies, which showed long sleep was associated with higher risk of NHL overall. Future directions include expanding our analysis to additional NHL subtypes, generating polygenic risk scores, and conducting stratified analyses. Citation Format: Pankhil Shah, Brittany Crawford, Anwar Merchant, Brenda Birmann, Angelica Macauda, Michelle A. Hildebrandt, Aaron Norman, Neil E. Caporaso, Meredith Yeager, Michael Dean, Immaculata De Vivo, Lynn Goldin, Nicola J. Camp, Rosalie Griffin, Delphine Casabonne, Federico Canzian, Pelin Unal, Elad Ziv, Catherine R. Marinac, Alexandra Nieters, Stephen J. Chanock, Mitchell J. Machiela, Michael Conry, Charlie Zhong, Hanla A. Park, Simon Cheah, Jonathan N. Hofmann, Elizabeth E. Brown, Celine Vachon, Susan Slager, Sonja Berndt, Sophia S. Wang, Vijai Joseph, James McKay, Henrik Hjalgrim, Lara Sucheston-Campbell, Karl Smith-Byrne, Alyssa Clay-Gilmour. Association between sleep traits and risk of non-Hodgkin's lymphoma subtypes: a mendelian randomization study in the International Lymphoma Epidemiology (InterLymph) Consortium [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7415.
Abstract 3250: Tumor-independent monitoring of minimal residual disease in multiple myeloma using cfDNA fragmentomics
Abelman, Dor , Eagles, Jenna , Wong, Aimée A., Shah, Saumil , Bridges, Sarah, White, Darrell , Song, Kevin , Murugesan, Alli , Reiman, Tony , Trudel, Suzanne , Wong, Aimee, Pedersen, Stephanie , Prokopec, Stephenie D. , Scott, David S., Sandhu, Irwindeep , Braggio, Esteban , Pugh, Trevor J.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 3250-3250

10.1158/1538-7445.am2025-3250 Get It

Abstract Introduction: Monitoring minimal residual disease (MRD) is critical in multiple myeloma (MM) to predict outcomes and guide therapy. Traditional bone marrow (BM) aspirates for MRD detection are invasive and limited by sample quality. We therefore explored cell-free DNA (cfDNA) fragmentation as a less invasive alternative for MRD detection. Methods: We performed 30-40X whole-genome sequencing (WGS) on peripheral blood cfDNA from 45 MM patients, collecting baseline (n = 45) and follow-up samples (n = 98) from eight Canadian sites (M4 and IMMAGINE studies) and one U.S. site (SPORE study), plus 25 healthy controls. Samples were collected post-induction therapy (n = 13), 100 days post-autologous stem cell transplantation (ACST, n = 36), and during maintenance therapy (n = 49). Multiparameter flow cytometry (MFC) MRD testing was conducted on 77 samples. We evaluated insert size metrics and MM-specific chromatin accessibility (from Ordoñez et al., 2020) using Griffin (described in Doebley et al., 2022). Results: Baseline samples had a higher proportion of short fragments (20-150 bp) than follow-up samples (p = 0.0037) and healthy controls (p = 0.019). A fragment score (FS) based on weighted fragment distribution (per Vessies et al., 2022) was highest at baseline (mean = -0.384), followed by MRD-positive (mean = -0.495) and MRD-negative (mean = -0.550) samples. MRD-negative FS was lower than baseline samples (p < 0.001) but higher than healthy controls (mean = -0.639; p = 0.016). Baseline samples had lower coverage at MM-specific chromatin regions than MRD timepoints (p < 0.05; baseline mean = 0.982; MRD-positive = 0.989; MRD-negative = 0.994; healthy = 0.993), suggesting higher transcriptional activity pre-treatment. MRD-negative samples had higher coverage than MRD-positive cases (p < 0.01). Using logistic regression, we assessed the predictive performance of FS and coverage at MM-specific sites. FS alone achieved an AUC of 0.632 (sensitivity [SN] 39.4%, specificity [SP] 92.1%, accuracy [AC] 67.6%). Coverage yielded an AUC of 0.681 (SN 75.8%, SP 60.5%, AC 67.6%). Combining FS and coverage at MM sites improved performance (AUC = 0.734; SN 48.5%, SP 92.1%, AC 71.8%). We next evaluated whether adjusting the BM tumor cell percentage cutoff by MFC could improve performance. At 0.017% (1 in 5, 789 cells) for MRD positivity, the combined model’s accuracy reached 83% with an AUC of 0.757 (SN 17%, SP 97%). Conclusions: cfDNA fragmentomic analysis achieved high specificity (92-97%) in detecting MRD, providing a less invasive alternative to facilitate serial monitoring. While sensitivity remains an area for improvement, the high specificity of cfDNA makes it valuable for confirming MRD negativity and reducing invasive procedures. Future efforts aim to enhance sensitivity by integrating additional fragmentomic features. Citation Format: Dor D. Abelman, Jenna Eagles, Aimee Wong, Saumil Shah, Stephanie Pedersen, Stephenie Prokopec, David S. Scott, Sarah Bridges, Darrell White, Irwindeep Sandhu, Kevin Song, Esteban Braggio, Alli Murugesan, Anthony Reiman, Suzanne Trudel, Trevor J. Pugh. Tumor-independent monitoring of minimal residual disease in multiple myeloma using cfDNA fragmentomics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3250.
Pentoxifylline use in alcohol-associated hepatitis with acute kidney injury does not improve survival: a global study
Idalsoaga, Francisco , Caldentey, Vicente, Arnold, Jorge , Maiwall, Rakhi , Qian, Steve , Elfeki, Mohamed A. , Khan, Mohammad Qasim, Mortuza, Rokhsana , Malhi, Gurpreet, Islam, Alvi H. , Ramírez, Carolina , Echavarria, Victor, Poca, María , Cuyàs, Berta , Ventura‐Cots, Meritxell , Tijera, María Fátima Higuera-De La, Al‐Karaghouli, Mustafa , Havaj, Daniel Ján , Shah, Vijay H. , Kamath, Patrick S. , SIMONETTO, DOUGLAS, Havaj, Daniel J , Shah, Vijay, Arab, Juan P , Poca, Maria , Ventura Cots, Meritxell , Elfeki, Mohamed A , Cuyas, Berta , Díaz, Luis Antonio , Dunn, Winston , Mehta, Heer, Ayares, Gustavo , Sarin, Shiv Kumar , Zhang, Wei , Simonetto, Douglas A. , Singal, Ashwani K. , Khan, Mohammad Qasim, Guizzetti, Leonardo , Cabezas, Joaquín , Echavarria, Victor, Soriano, German , Abraldeṣ, Juan G. , Skladaný, Lubomir , Rincón, Diego , Arrese, Marco , Bataller, Ramon A , Arab, Juan Pablo

Mayo Clinic

eGastroenterology | April 20, 2025 | Volume: 3 | Issue: 2 | Pages: e100179

10.1136/egastro-2024-100179 | PMID 40276593 Get It

Background Severe alcohol-associated hepatitis (sAH) is a life-threatening condition with high mortality, where corticosteroid use is the only treatment that has shown short-term benefits. Pentoxifylline, an anti-tumour necrosis factor-alpha agent, has been proposed for its potential to improve outcomes, especially in patients with acute kidney injury (AKI). We aimed to evaluate the impact of pentoxifylline on mortality in patients with sAH and AKI in a well-characterised global cohort. Methods We conducted a retrospective, registry-based study including patients meeting the National Institute on Alcohol Abuse and Alcoholism clinical criteria for sAH and AKI. Mortality was the primary endpoint, with liver transplantation as a competing risk. Statistical analysis included Cox regression and Kaplan-Meier survival estimates. Results We included 525 patients from 20 centres across eight countries. The median age was 48 years, with 26.1% females, and 76.9% had a history of cirrhosis. Multivariable Cox regression models showed that pentoxifylline use was not associated with survival (HR 1.20, 95% CI 0.85 to 1.69, p=0.291). Factors associated with mortality included age (HR 1.23, 95% CI 1.10 to 1.36, p<0.001), Model for End-Stage Liver Disease score at admission (HR 1.06, 95% CI 1.04 to 1.08, p<0.001) and renal replacement therapy use (HR 1.39, 95% CI 1.05 to 1.84, p=0.019). The main causes of death were multiple organ failure (42%), infections (10%), oesophageal varices bleeding (7%) and renal failure (6%). Conclusion Pentoxifylline showed no significant benefit on mortality in patients with sAH and AKI. Further studies are needed to refine treatment strategies for this high-risk group.
Pomalidomide: A Step on the PATH Forward for Treatment of Hereditary Hemorrhagic Telangiectasia
Wolf, Emily, Wysokinska, Ewa , Shah, Surbhi

Mayo Clinic

The Hematologist | April 18, 2025 | Volume: 22 | Issue: 3 | Pages: No page available

10.1182/hem.v22.3.202535 Get It

Abstract P1157: Changes in Artificial Intelligence-Enabled Electrocardiogram-Derived Age During Mental Stress Testing and Risk of Major Adverse Cardiovascular Events in Patients With Coronary Heart Disease
Vaccarino, Viola , Medina-Inojosa, Betsy, Ko, Yi‐An , Alkhoder, Ayman , Quyyumi, Arshed A. , Medina‐Inojosa, José R. , Attia, Zachi I. , Shah, Anish S. , Medina‐Inojosa, Betsy J. , Soliman, Elsayed Z. , Kapa, Suraj , López-Jiménez, Francisco , Shah, Amit

Mayo Clinic

Circulation | April 17, 2025 | Volume: 151 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.151.suppl_1.p1157 Get It

Background: The gap between artificial intelligence-derived age (ECG-Age) and chronological age has been validated as a strong predictor of increased cardiovascular morbidity and mortality, independent of age, and is a potential biomarker of biological aging. Acute stress may cause real-time, transient changes in autonomic function via electrophysiological signals that, when repeated over time, may contribute to biological aging and represent mechanisms linking stress and Major Adverse Cardiovascular Events (MACE). We hypothesized that acute mental stress induced in a laboratory is associated with increased ECG and that this increase is associated with a higher risk of MACE among individuals with stable coronary heart disease (CHD). Methods: We pooled two prospective cohorts of participants with stable CHD from a university-based hospital network in Atlanta. Stress was induced using a standardized mental stress test (public speaking task) and measured 12-lead ECGs during rest, mental stress, and recovery periods. To measure ECG-age, we utilized a published algorithm using a neural network on >500,000 independent patients. The study endpoint was MACE including nonfatal myocardial infarction, hospitalization for heart failure, or cardiovascular death. The difference in ECG-Age between resting and acute mental stress was used to define the stress Age-Gap. Cox proportional hazard regression modeled the association of stress Age-Gap operationalized as tertiles adjusting for chronological age, sex, race, cardiovascular risk factors, and baseline Cohen perceived stress scale. Results: 442 participants in the total sample pool (38% women). Over a 5-year median follow-up, 95 participants (21%) experienced MACE. At rest, the mean chronologic age was 55.7±9.9 years, and ECG-Age was 57.1 ±10.7 years, with rest Age-Gap of 0. 9±9.6 (p=0.16). During stress, the stress Age-Gap of 1.95±9.8 (p<0.0001), while recovery Age-Gap was 1.1±10.3 (p=0.13). Those that demonstrated the largest ECG-Age positive change between rest and stress by ECG (top tertile) had a higher risk for MACE when compared to those with the lowest or negative ECG age change (bottom tertile), see Figure. Conclusion: Among patients with stable CHD, acute mental stress caused changes in biological age as measured by AI-ECG consistent with accelerated biological aging. Such changes were associated with MACE. These results uncover accelerated biological aging as a mechanism linking acute stress to CVD outcomes.